![Page 1: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/1.jpg)
Peritoneal spread risk in Gastric , Pancreatic and Colon cancers
www.slideshare.net/GinaBrown3
![Page 2: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/2.jpg)
Understanding patterns of failure
• Improvements in surgical technique• Identification of subgroups benefiting from
preoperative therapy• Refine radiotherapy Rx volumes• Primary endpoint of rectal cancer trials
![Page 3: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/3.jpg)
Predictable patterns of recurrence
• Tumour spillage• CRM involvement• Peritoneal perforation• Distal margin involvement• Residual disease
![Page 4: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/4.jpg)
Space of Retzius
Bladder
mesorectum
rectum
peritoneal
peritoneum
Mesorectal fascia
![Page 5: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/5.jpg)
Post surgical pelvis
![Page 6: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/6.jpg)
Post TME pelvis
![Page 7: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/7.jpg)
![Page 8: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/8.jpg)
Marginal pattern of recurrence
Starling, Scott-Mackie, Brown et al 2005
![Page 9: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/9.jpg)
CRM involvement and later recurrence
![Page 10: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/10.jpg)
Marginal recurrence
![Page 11: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/11.jpg)
Anastomosis
![Page 12: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/12.jpg)
Anastomotic recurrences
![Page 13: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/13.jpg)
Tumour spillage
![Page 14: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/14.jpg)
Perineal recurrence
Perineal
![Page 15: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/15.jpg)
Hydronephrosis = strong likelihood of local recurrence
Brown et al Clinical Radiology 2003
75 patients, new hydronephrosis is a predictor for peritoneal recurrence (90% of patients).
![Page 16: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/16.jpg)
Peritoneal perforation
![Page 17: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/17.jpg)
Distal margin involvement
![Page 18: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/18.jpg)
Nodal recurrence
![Page 19: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/19.jpg)
Nodal recurrence
![Page 20: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/20.jpg)
Krukenberg Tumours
![Page 21: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/21.jpg)
Relapse Pattern No of Patients n=70
(a) Marginal (around the margins of the surgical bed)
43.9%
(b) Lymph node (internal or external iliac groups)
24.3%
(c) Pelvic peritoneal 22.0%
(d) Perineal 14.6%
(e) Anastomotic 12.2%
(f) Krukenberg 2.4%
![Page 22: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/22.jpg)
• MDT 2007-09• 296 sigmoid cancers • 104 for palliative care
• Curable sigmoid cancers: n=192• No FU data at all: n=42• With FU: n=150• FU 36 months (range 1-76, median 38)
• Recurrence: 62/192 (32%) • Local recurrence: 19 (11%)
Recurrence sigmoid cancer
![Page 23: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/23.jpg)
High risk features
• Tumour involving non peritonealised fascial margin
• Tumour penetration of adjacent organs• 4 or more involved nodes• Extramural venous invasion• Depth of extramural spread >5mm
![Page 24: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/24.jpg)
Eur J Surg Oncol. 2005 Oct;31(8):845-53.
Improved survival
![Page 25: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/25.jpg)
Are we able to preoperatively identify poor prognostic features in colon cancer?
![Page 26: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/26.jpg)
Burton 2006 Int. J. Radiation Oncology Biol. Phys
![Page 27: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/27.jpg)
• Primary surgery n=57
• 16 at/above peritoneal reflection
• 19 rectosigmoid• 22 sigmoid
• Neoadj CRTx + surgery n=18
• 9 at/above peritoneal reflection
• 5 rectosigmoid • 4 sigmoid
Burton 2006 Int. J. Radiation Oncology Biol. Phys
![Page 28: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/28.jpg)
MRI predicted prognosis with final histological prognosis in 57 patients undergoing primary surgery
Final histological prognosis
Good Poor TotalMRI Good 31 6 37
PredictedPrognosis Poor 10 11 21
Totals 41 17 5884% (CI =72.6-92.7%) accuracy for MRI prediction of prognosisKappa = 0.63Sensitivity = 90%Specificity = 72%Positive predictive value = 88%Negative predictive value = 76%
Burton 2006 Int. J. Radiation Oncology Biol. Phys
![Page 29: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/29.jpg)
Diagnostic dilemmas – is it recurrent disease or not?
• Mass - ? Significance• Scar vs recurrence• PET-ve• Inflammatory collection vs recurrence
![Page 30: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/30.jpg)
New Mass
Examples of reporting criteria
![Page 31: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/31.jpg)
Importance of baseline review
2004 2000
![Page 32: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/32.jpg)
Peritoneal pelvic recurrence
![Page 33: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/33.jpg)
Scar vs Recurrence
![Page 34: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/34.jpg)
Collection vs Recurrence
![Page 35: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/35.jpg)
PET-ve
![Page 36: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/36.jpg)
Anatomical information – to plan resection/resectability
• Which compartment?• Which sacral level?• Multifocal vs unifocal – High res MRI
essential• Distant metastases, review of both contrast
enhanced MDCT and CT-PET helpful• Trial of chemotherapy/RT prior to radical
surgery – response assessment
![Page 37: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/37.jpg)
Operation likely? – yes/ probably no
• Yes:– Central compartment– Anterior compartment
below peritoneal reflection
– Posterior compartment below S2
– Perineal
• Probably no:– Lateral compartment– Sciatic nerve infiltration
(coronal imaging)– S1/S2 sacral infiltration– Peritoneal perforation
![Page 38: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/38.jpg)
Post TME pelvis
![Page 39: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/39.jpg)
Central compartment
![Page 40: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/40.jpg)
Post Chemo
![Page 41: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/41.jpg)
Lateral compartment
![Page 42: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/42.jpg)
Key messages
• Know patterns of recurrence• Familiarity with post surgical pelvis• FDG PET-CT helpful tool • Growing mass on CT/MRI with elevated CEA =
diagnostic of recurrence
![Page 43: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/43.jpg)
Conclusions
• GI Radiologists now play a key role in the MDT for detecting and selecting patients with recurrent disease for radical treatment– Aggressive imaging based follow up of high risk
patients results in earlier detection increases survival
– Anatomic delineation and characterisation of lesions using both MDCT/MRI with contrast
– Careful use of multimodality imaging in assessing extent of disease (PET/MRI/CT)
![Page 44: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/44.jpg)
Gastric cancer risk factors
• Published evidence – clinico pathological risk features
• Imaging assessment of gastric cancer• Delineation of the primary tumour• Nodal disease versus extranodal disease and
its depiction on CT
![Page 45: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/45.jpg)
![Page 46: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/46.jpg)
![Page 47: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/47.jpg)
Pancreatic cancer
• T4 and transperitoneal seeding– Known Mechanisms of transperitoneal spread in
pancreatic cancer and rates of PC– Lymphatic– Vascular– Implantation and seeding
![Page 48: Peritoneal spread risk in gastric, pancreatic and colon cancers](https://reader035.vdocuments.net/reader035/viewer/2022070601/587e633b1a28ab2a538b675f/html5/thumbnails/48.jpg)
For the group to develop in future:
• More work in determining imaging features at baseline for peritoneal relapse T category is too broad and crude a tool
• Improve documentation of tumours at baseline and compare against outcomes
• Patterns of spread are key• Proforma reporting and consistent
documentation at diagnosis and at relapse is essential